NL-OMON41146
Withdrawn
Not Applicable
Combo Bio-Engineered Sirolimus Eluting Stent Placement Long-Term Healing Pattern Assessment by Optical Coherence Tomography - COMBO Healing
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- incidence of intracoronary thrombi and late loss
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 40
- Status
- Withdrawn
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. The patient must be \*18 and \* 80 years of age;
- •2\. Device and procedural success at the index procedure;
- •3\. The Patient is willing to comply with specified follow\-up evaluations;
- •4\. The Patient or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has been provided written informed consent, approved by the appropriate Medical Ethics Committee (MEC), Institutional Review Board (IRB), or Human Research Ethics Committee (HREC).
Exclusion Criteria
- •1\. Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following index procedure. Female patients of childbearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test;
- •2\. Impaired renal function (serum creatinine \>2\.0 mg/dL or 177 \*mol/l) or on dialysis;
- •3\. Platelet count \<100,000 cells/mm3 or \>700,000 cells/mm3 or a WBC\<3,000 cells/mm3;
- •4\. Patient has other medical illness (e.g., cancer, known malignancy, or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non\-compliance with the protocol, confound the data interpretation or is associated with
- •5\. a limited life expectancy (i.e., less than 1 year);
- •6\. Patient has a known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel/ticlopidine, prasugrel, stainless steel alloy, sirolimus, everolimus and/or contrast sensitivity that cannot be adequately pre\-medicated;
- •7\. Patient has received any organ transplant or is on a waiting list for any organ transplant;
- •8\. Any significant medical condition, which in the Investigator\*s opinion may interfere with the patient\*s optimal participation in the study;
- •9\. Currently participating in another investigational drug or device study or patient in inclusion in another investigational drug or device study during follow\-up;;Angiographic exclusion criteria
- •10\. Patients treated for in\-stent restenosis of the index procedure Combo stent during follow\-up;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Sirolimus-coated balloon versus drug-eluting stent in native coronary vesselsNL-OMON54209Fondazione Ricerca e Innovazione Cardiovascolare, No profit organization315
Not yet recruiting
Not Applicable
Sirolimus-coated balloon versus drug-eluting stent in native coronary vesselsNL-OMON22515Fondazione Ricerca e Innovazione Cardiovascolare ETS1,130
Completed
Not Applicable
Sirolimus Eluting Angioplasty Balloon for In-Stent REstenosis (SABRE) Trialcoronary heartdiseaseIn-stent restenosis10011082NL-OMON41496Caliber Therapeutics, Inc.10
Unknown
Not Applicable
Biomime Stent in All-comers PCI Patients RegistryCoronary Artery DiseaseNCT02398955Azienda Ospedaliero Universitaria Maggiore della Carita250
Completed
Not Applicable
BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) European Angiography Studycoronary artery diseasecoronary artery stenosis10011082NL-OMON47919Medinol Lid.49